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ABSTRACT
Background: As to nutritional therapy, continuous discussions were observed concerning 
calorie restriction (CR) and low-carbohydrate diet (LCD). Authors and colleagues have applied 
LCD for lots of diabetic patients and reported the detail relationship with ketone bodies and 
Morbus (M) value.
Methods: Ninety-three patients with type 2 diabetes mellitus (T2DM) were considered as 
subjects in the study, among which 51 were male and 52 were female, 58.3±13.2 years old 
on average, 60 years old in median. Methods were as follows: 1) patients were admitted and 
provided formular diet, which included CR diet (60% carbohydrates, 1400 kcal/day) on day 
1-2, and LCD (12% carbohydrate, 1400 kcal/day) on day 3-14; 2) several biomarkers on fasting 
were measured on day 2, 4 and 14; 3) daily profile of blood glucose were done on day 2 and 
day 4.
Results: According to the M-value, subjects were classified into 4 groups, which were less 
than 25, 26-100, 101-250, more than 251, and number was 24, 24, 24, 21, respectively. The 
average HbA1c in 4 groups were 6.6%, 7.4%, 8.5% and 9.5% respectively. The median 
M-values decreased from day 2 to 4, which were 10.4 to 9.1, 53.5 to 7.7, 150 to 19.1 and 438 
to 87, respectively. The average uric acid in each group revealed significant increase from day 
2 to day 14. There were significant correlation between uric acid increment and creatinine 
increment, and among creatinine, creatinine clearance (CCr) and Cystatin C. 
Conclusion: LCD showed efficacy for glucose variability with significant decrease in glucose 
and M-value. Renal study showed increase of serum uric acid. In addition to correlations of 
Cystatin C and biomarkers, current results would be from some dehydrated state and/or relative 
decrease of total calorie intake. These findings would become the fundamental data of efficacy 
of LCD and its physiological influences for renal function.
KEY WORDS: Low-carbohydrate diet (LCD); Morbus value (M-value); Cystatin C; Creatinine; 
Type 2 diabetes mellitus (T2DM).
ABBREVIATIONS: LCD: Low-Carbohydrate Diet; CR: Calorie Restriction; T2DM: Type 2 
Diabetes Mellitus; MAGE: Mean Amplitude of Glycemic Excursions; M-value: Morbus value; 
CGM: Continuous Glucose Monitoring, SMBG: Self-Monitoring of Blood Glucose; CKD-
EPI: Chronic Kidney Disease-Epidemiology Collaboration; MDRD: Modification of Diet in 
Renal Disease; CCr: Creatinine Clearance, eGFR: estimated Glomerular Filtration Rate; GFR: 
Glomerular Filtration Rate; T1DM: Type 1 Diabetes Mellitus; UA: Uric Acid.
INTRODUCTION
As to adequate nutritional therapy with metabolic and diabetic patients, the discussion has been 
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continued for long in the light of calorie restriction (CR) and 
low-carbohydrate diet (LCD).1,2 Several researcher showed the 
predominant efficacy of LCD compared with CR.3-8 Recently, 
Bernstein and Feinman have suggested adequate definition and 
treatment of LCD, in addition to the statement of American Dia-
betes Association (ADA).1
 In Japan, authors and colleagues have treated lots of 
patients with diabetes mellitus, and investigated the efficacy of 
LCD.9-11 For medical and social development of LCD, we pro-
posed 3 types of actual LCD in daily life, which are petit, stan-
dard and super LCD.9,12.13 We have also reported the significant 
role of ketone bodies in LCD and physiological role for pregnant 
female and fetus newborn axis.11,14
 Furthermore, we investigated the clinical significance 
of Morbus (M) value in the treatment of LCD for the patients with 
type 2 diabetes mellitus (T2DM).11,12 M-value is useful marker in 
the evaluation for blood glucose variability in diabetic patients 
that expresses both elevated glucose level and increased mean 
amplitude of glycemic excursions (MAGE).15-17 When glycemic 
control gets better, numerical value of M-value decreases highly, 
which is simple and helpful for clinical and medical practices 
and research.
 In this study, we have treated T2DM patients for super 
LCD and investigated the changes of average blood glucose, 
M-value and renal biomarkers such as uric acid, creatinine and 
Cystatin C.
SUBJECTS AND METHODS
The subjects were 93 patients with T2DM, including 41 males 
and 52 females, with 58.3±13.2 years old (mean±SD), and 60 
years in median value. They were admitted for 14 days, and 
received the same treatment protocol for endocrine, metabolic 
and renal examination.
 The methods included formula diet and examination. 
On admission, CR diet was given on day 1 and 2, including 60% 
carbohydrates, 25% lipids and 15% protein with 1400 kcal/day. 
After that, LCD was given from day 3 until day 14, including 
12% carbohydrates, 64% lipids and 24% protein with 1400 kcal/
day, which is so-called super LCD formula used for long years 
in our investigation.9-12
 We measured several biomarkers on day 2, 4 and 14. 
On day 2, the basal biomarkers such as blood glucose/HbA1c, 
seru M-value of uric acid, creatinine, cystatin C, and daily profile 
of blood glucose were measured. On day 4, daily profile of blood 
glucose was measured. On day 14, uric acid, creatinine and other 
biomarkers were measured.
 One subject who is 64-years-old man with HbA1c 7.3% 
had 3 times of daily profile of glucose. The average glucose and 
M-value were calculated for that subject. 
Analysis for M-value
The M-value (Morbus value) stands for the combination of 
two factors. One is the level of blood gluose, and another is the 
MAGE. It is a logarithmic transformation of the deviation of 
glycemia from an arbitrary assigned “ideal” glucose value.15-17 
The formula is as follows: M = MBS+MW, where MW=(maximum 
blood glucose-minimum glucose)/20; MBS=the mean of 
MBSBS; MBSBS=individual M-value for each blood glucose 
value calculated as (absolute value of [10×log (blood glucose 
value/120)]3).
 
 
 For the M-value, the standard range is <180, borderline 
is 180-320 and abnormal is >320. Whereas in the M-value, the 
standard range is <5, borderline is 5-10 and abnormal is >10. It 
was reported that multiple sampling and a 7-point glycemic trial 
per day would have yielded similar results.17
Statistical Analyses
In current study, data was represented as the mean±standard de-
viation, and also represented median, quartile of 25% and 75% 
in biomarkers. For statistical analyses, correlation coefficients 
were calculated using the Microsoft Excel analytical tool.18 Fur-
thermore, we used JMP (Version 8) statistical analysis software 
(JMP Japan Division of SAS Institute Japan Ltd., Minato-ku, 
Tokyo, Japan) and Microsoft Excel analytical tool. A signifi-
cance level of less than 5% obtained using a two-tailed test was 
considered to be statistically significant. 
Ethical Considerations
Current study was conducted in compliance with the ethical 
principles of the Declaration of Helsinki and Japan’s Act on the 
Protection of Personal Information along with the Ministerial 
Ordinance on Good Clinical Practice (GCP) for Drug (Ordinance 
of Ministry of Health and Welfare No. 28 of March 27, 1997). 
No ethical committee meeting was held. Informed consent was 
obtained from the subjects related to this research. The study 
was registered with UMIN #R000031211.
RESULTS
Fundamental data
The results obtained from 93 subjects were shown in Table 1. 
By the level of M-value, subjects were classified into 4 groups. 
Group 1-4 revealed the M-value, less than 25, 26-100, 101-250, 
more than 251, with the number of the cases 24, 24, 24, 21, 
respectively.
Open Journal
http://dx.doi.org/10.17140/DROJ-3-133ISSN 2379-6391
DIABETES RESEARCH
Diabetes Res Open J Page 33
Glucose Metabolism and M-value
The results for HbA1c, fasting glucose and M-value were 
shown in Table 2. M-value in 4 groups decreased from day 2 
to 4, which was 10.4 to 9.1, 53.5 to 7.7, 150 to 19.1 and 438 to 
87, respectively (Figure 1). The average glucose and M-value of 
64-years-old patient with T2DM were shown in Table 3.
Renal Function
Renal biomarkers on day 2 and day 14 were shown in Table 
4. The average uric acid (UA) level in each group revealed 
significant increase from day 2 to day 14. (Figure 2) There was 
significant correlation between UA increment and creatinine 
increment on day 2 and day 14 (Figure 3). Other markers did not 
Table 1: General Data of the Subjects.
Categorization Group 1 Group 2 Group 3 Group 4
Number 24 24 24 21
Sex (male/female) 13/11 8/16 9/15 11/10
Age in average (y.o.) 56.2±13.3 59.1±15.1 62.8±7.4 54.7±15.1
Age in median (y.o.) 57 (47-64) 63 (50-72) 63 (58-68) 60 (50-65)
Body Mass Index (kg/m2) 23.8±3.0 24.2±5.2 25.4±4.2 27.3±5.2
M-value on day 2 4-25 26-100 101-250 251-1285
The results were expressed by Mean±SD.
The results of age were also expressed by median (25%-75%).
Table 2: HbA1c, Glucose and Morbus (M) Value of the Subjects.
Categorization Group 1 Group 2 Group 3 Group 4
HbA1c
HbA1c on day 2 in average (%) 6.6±1.1 7.4±1.3 8.5±1.2 9.5±1.7
HbA1c on day 2 in median (%) 6.4 (6.1-6.8) 7.3 (6.3-8.2) 8.4 (7.6-9.4) 9.0 (8.6-10.6)
Fasting Glucose
Fasting Glucose on day 2 (mg/dL) 117.3±20.4 146.5±31.3 183.5±42.5 226.5±38.5
Fasting Glucose on day 4 (mg/dL) 110.5±42.7 125.2±27.0 147.7±30.6 186.8±43.3
Fasting Glucose on day 14 (mg/dL) 98.9±15.0 110.3±21.3 119.2±24.4 133.1±42.1
Average Glucose
average glucose on day 2 (mg/dL) 128.2±11.8 163.6±46.2 211.1±20.3 298.6±46.3
average glucose on day 4 (mg/dL) 111.6±19.2 135.5±32.2 159.0±21.7 198.2±47.7
Morbus value
M value on day 2 10.4 (6.2-17.7) 53.5( 41-67) 150 (125-194) 438 (343-701)
M value on day 4 9.1 (4.4-14.3) 7.7 (3.9-19.9) 19.1 (14.0-29.9) 87.0 (33-148)
The results were expressed by Mean±SD.
The results of HbA1c and M value were expressed by median (25%-75%).
The M-values in 4 groups were investigated on day 2 and 4. The median levels on day 2 to day 4 in 4 groups 
were 10.4 to 9.1, 53.5 to 7.7, 150 to 19.1 and 438 to 87, respectively. All subjects were provided calorie 
restricted (CR) diet on day 1 and 2, and low carbohydrate diet (LCD) on day 3 and 4. Abbreviation: 1-CR 
means group 1 and Calorie Restriction on day 2, and 4-LCD means group 4 and Low Carbohydrate Diet 
on day 4. 
Figure 1: Changes of M-value on Day 2 and 4 in 4 Groups.
Open Journal
http://dx.doi.org/10.17140/DROJ-3-133ISSN 2379-6391
DIABETES RESEARCH
Diabetes Res Open J Page 34
Table 3: Average Glucose and M-value of Patient with T2DM.
Blood Glucose level (mg/dL)
M-value
Time (h) 8 10 12 14 17 19 21 Average
Day 2 180 315 288 335 268 333 304 289 426.0
Day 4 140 191 185 180 152 166 160 168 29.0
Day 14 97 124 112 125 86 104 93 106 7.4
The patient was 64-years-old male with HbA1c 7.3%.
He was on CR on day 1,2 and LCD on day 3-14.
Blood glucose was measured 7 times a day from 08:00 h to 21:00 h.
M-value stands for combined implication of both average glucose and Mean Amplitude of Glycemic 
Excursions (MAGE).
Table 4: Renal Function of the Subjects.
Categorization Group 1 Group 2 Group 3 Group 4
Uric Acid
Uric Acid on day 2 (mg/dL) 5.45±1.37 4.90±1.46 5.33±1.36 4.89±1.40
Uric Acid on day 14 (mg/dL) 6.59±1.92 6.19±.2.01 6.18±1.29 5.90±1.63
Uric Acid increment (mg/dL) 1.01±1.03 1.12±1.02 1.22±1.06 1.12±1.03
Creatinine
Creatinine on day 2 (mg/dL) 0.75±0.15 0.70±0.17 0.76±0.21 0.64±0.15
Creatinine on day 14 (mg/dL) 0.81±0.18 0.77±0.16 0.80±0.23 0.72±0.17
Blood Urea Nitrogen
BUN on day 2 (mg/dL) 18.5±5.0 18.3±4.8 19.3±7.4 17.5±4.3
BUN on day 14 (mg/dL) 22.3±7.2 21.2±5.3 21.6±11.1 17.9±3.8
Other markers
Cystatine C on day 2 (mg/L) 0.81±0.18 0.79±0.17 0.83±0.32 0.69±0.15
CCr on day 4 (ml/min) 99.7±25.3 96.3±29.7 95.9±27.2 115.3±25.3
eGFR on day 4 (ml/min) 78.6±19.9 75.9±23.4 75.6±21.4 90.9±19.9
u-uric acid/creatinine 0.42±0.11 0.52±0.18 0.53±0.13 0.61±0.22
The results were expressed by Mean±SD.
Uric acid (UA) levels were investigated in group 1-4 on day 4 and day 14. The average UA level in each group 
revealed significant increase from day 2 to day 14. The asterisk represents as follows: *p<0.05, **p<0.01. 
Gr1-d2: Group 1 day 2; Gr4-d14: Group 4 day 14. 
Figure 2: Changes of Uric Acid on Day 2 and 14 in 4 Groups.
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show any significant difference in 4 groups.
 There was no significant correlation between UA in-
crement from day 2 to 14 and Cystatin C. There was negative 
significant correlation between Creatinine Clearance (CCr) and 
Cystatin C. (Figure 4). There was positive significant correlation 
between Creatinine and Cystatin C (p<0.01) (Figure 5).
DISCUSSION
LCD was introduced by Bernstein and Atkins, and got developed 
for long years.19,20 Successively, the effect of LCD have been 
reported.21-24 In Japan, we have continued clinical study and 
research concerning LCD, and reported effect of weight 
reduction, elevated ketone bodies and its physiological role and 
Figure 3: Correlation between Uric Acid Increment and Creatinine Increment on Day 2 
and Day 14.
 There were significant correlation between both factors (p<0.05).
Figure 4: Correlation between Creatinine Clearance and Cystatin C.
There were negative significant correlation between both factors (p<0.01). 
There were positive significant correlation between both factors (p<0.01). 
Figure 5: Correlation between Creatinine and Cystatin C.
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significant evaluation using M-value.11,12
 M-value is a useful biomarker to express the variability 
of blood glucose including glucose level and fluctuation. There 
were discussions concerning how many times of sampling per 
day is necessary. It was reported that multiple sampling and 
a 7-point glycemic trial per day would have yielded similar 
results.25-27
 M-value reveals similar result for continuous glucose 
monitoring (CGM) for 48 hours which is considered as ideal re-
search method.28 There are rare reports concerning M-value. Pa-
tients with T1DM were investigated for blood glucose fluctua-
tions 3 times and more per day, using CGM and self-monitoring 
of blood glucose (SMBG).29
 In this study, the data of M-value and HbA1c in 4 groups 
showed parallel relation. M-value on day 4 was decreased than 
that on day 2, suggesting clinical short effect of LCD. 
 In previous reports, microalbuminuria and glomerular 
filtration rate (GFR) were followed 14 years, and they did not 
vary in relation to diabetes status.30,31 Continuing LCD with 14% 
carbohydrate for 1 year, obese adults with T2DM had no adverse 
affect on clinical markers of renal function or on preexisting 
kidney disease.32 Similar results were obtained for creatinine, 
eGFR, albuminuria, or fluid and electrolyte balance.33-34
 LCD is as safe as CR and Mediterranean, in preserv-
ing/improving renal function among moderately obese partici-
pants with or without type 2 diabetes.35 Potential improvement 
is likely to be mediated by weight loss-induced improvements in 
insulin sensitivity and blood pressure. For LCD for a year, pa-
tients with stage 1-3 renal disease had an improvement in renal 
function, whereas patients with hyperfiltration had a decrease in 
the GFR.36
 Our current study showed that uric acid was significantly 
elevated from day 2 to day 14 in 4 groups. One of the causes of 
elevated uric acid was supposed to be some dehydrated status 
i.e., less water intake than expected. This is compatible with 
the result of significant correlation with elevated uric acid and 
elevated creatinine, with similar elevated tendency of BUN. 
Another probable cause would be the relative decrease of total 
calorie intake. When nutrition changes from CR to LCD, total 
calorie often decreases compared with that of previous status. 
Third possible cause would be the hyperfiltration of glomerulus 
in early stage of diabetic nephropathy. As the degree of hyper-
filtration becomes less, creatinine and uric acid values could be 
increased.36 These speculation are possible because of sports for 
years.
 In comparison with previous reports for years, our 
study is based on a short period of 2 weeks. Consequently, our 
speculation would be possibility due to limited research protocol.
 
 In this study, Cystatin C showed significant positive 
correlation with creatinine and negative correlation with 
creatinine clearance. Serum Cystatin C alone provides GFR 
estimates that are nearly as accurate as serum creatinine adjusted 
for age, sex and race.37 The chronic kidney disease-Epidemiology 
collaboration (CKD-EPI) creatinine equation was reported to 
be more accurate than the modification of diet in renal disease 
(MDRD) Study equation.38 Recently, the combined creatinine-
Cystatin C equation have been precise and useful for various 
patho-physiological states including T2DM.39-41 Our results 
would become reference data among renal biomarkers in clinical 
terms which represents actual interrelationship on LCD in the 
patients with T2DM.
 Our study has small and limited research situation, then 
further research will be necessary concerning the renal functions 
in LCD.1 LCD would be highly evaluated for treatment of 
diabetes with the clinical research of influence for renal function.
CONCLUSION
In this study, the changes of M-value on CR/LCD, creatinine, 
uric acid and cystatin C were investigated in patients with 
T2DM. Decreased M indicates the efficacy of LCD for short 
period, and influence for renal biomarkers in detail relationship 
will be studied in the future.
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